When EMBL alumnus Norbert Kraut walks into a cancer conference today, it’s often with exciting updates for the cancer community.
Kraut, now a senior executive scientist at Boehringer Ingelheim, has spent the last decade leading large international oncology research teams. One of their major achievements: a new HER2-targeted tyrosine kinase inhibitor for a rare form...
